Skip to Main Content

Eli Lilly announced Tuesday that adding its drug Verzenio to hormone blockers decreased the risk of a relapse of breast cancer in women who had had their tumors removed.

The result makes Verzenio the first drug in its class, a group of breast cancer medicines known as CDK 4/6 inhibitors, to work in this early stage of treatment, called the adjuvant setting. The drugs are currently used in women whose breast cancer is metastatic, meaning that tumors have spread to other parts of their bodies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!